Navigation Links
EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
Date:11/26/2012

ROCKVILLE, Md., Nov. 26, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing targeted therapeutics for the treatment of cancer, announced today the publication of favorable results of a preclinical study in breast cancer of its oral Aurora A/angiogenic kinase inhibitor, ENMD-2076. 

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO )

The article, entitled "Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models" reports evidence that ENMD-2076 exhibited robust anticancer activity against breast cancer cell lines lacking expression of the estrogen receptor (ER), progesterone receptor (PR) and without HER2‑amplification: a particularly difficult to treat subtype termed "triple-negative" breast cancer (TNBC).  TNBC is associated with a shortened disease-free and overall survival at all stages of diagnosis when compared to other breast cancer subtypes.  Candidate predictive biomarkers were also identified which may be useful in selecting patients that are particularly sensitive to this compound, ENMD-2076, in the future. 

In this study, a diverse panel of twenty-nine breast cancer cell lines representative of the clinically defined breast cancer subtypes were exposed to ENMD-2076 and the effects on proliferation, apoptosis, and cell cycle distribution were evaluated.  ENMD-2076 demonstrated more robust activity against cell lines of the TNBC subtype compared to the luminal and HER2-amplified subtypes.  This in vitro activity was confirmed in vivo, in MDA-MB-468 and MDA-MB-231 TNBC xenografts.  Baseline gene expression profiling and pathway analysis of the panel revealed that p53 and G1/S cell cycle pa
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dana-Farber Cancer Institutes Ursula A. Matulonis, MD Article on EntreMeds ENMD-2076 Published in the European Journal of Cancer
2. EntreMed Reports Second Quarter 2012 Financial Results
3. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
4. EntreMed Reports First Quarter 2012 Financial Results
5. Trovagene Announces Closing of Private Placement of $3.76 Million from the Sale of Restricted Common Stock and Warrants
6. ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment
7. AspenBio Pharma Announces Closing of Public Offering of 1,946,000 Shares of Common Stock
8. Vasomedical Announces Financial Results for the Third Quarter of 2012
9. Proteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121
10. Ohr Pharmaceutical Announces Additions to Ophthalmic Scientific Advisory Board
11. NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... Disorders Drug Pipeline Insight 2014" report to their offering. ... in US is one of the largest segments of pharmaceuticals ... alarming rate, while the available therapies were unable to meet ... in the market for CNS disorder, especially over the past ...
(Date:8/29/2014)... Research and Markets has announced the addition ... Pharmaceutical Equipment Market in China, 2014-2018" report to ... Forecast of Pharmaceutical Equipment Market in China ... pharmaceutical equipment industry in the aspects of current ... performance of domestic major enterprises, as well as offers ...
(Date:8/29/2014)... According to the new ... (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, ... Synthesis, NGS, DNA, RNAi) - Global Forecast to ... Market is expected to reach $1,712.1 Million by ... a CAGR of 9.8% from 2014 to 2019.. ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... HAMILTON, N.J., Sept. 14 MedAvante, Inc., the leader ... that the U.S. Food and Drug Administration (FDA) has ... psychiatric medication including primary outcome data collected by MedAvante ... a Johnson & Johnson company, submitted the NDA for ...
... privately-held biotechnology company focused on developing a novel class ... Quinton Oswald has joined the company as Chief Executive ... experience and management expertise to the CEO role. Most ... President & Business Unit Head for the Tissue Growth ...
Cached Medicine Technology:FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters 2FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters 3Quinton Oswald Named Chief Executive Officer of SARcode Corporation 2Quinton Oswald Named Chief Executive Officer of SARcode Corporation 3
(Date:8/30/2014)... 2014 Patients suffering from vitiligo can ... a new review published by Daily Gossip. , ... so there is no wonder that numerous sufferers search ... Vitiligo Treatment is one of the most appreciated such ... promises to stop the spread of this disorder immediately, ...
(Date:8/30/2014)... 30, 2014 The Plastic Surgery Group ... Jersey and even in the U.S. to provide clients ... off of patients’ waists with deep-tissue heating. , Unlike ... sections, Vanquish is more inclusive to target large sections ... comfortably under panels about one inch away from their ...
(Date:8/30/2014)... 30, 2014 The establishment and ... has been one of the main strategies of ... a positive impact around the world. , Architecturally ... top trained executives and trainers deliver L. Ron ... Vital statistics demonstrate that significant reduction in ...
(Date:8/30/2014)... Richmond, VA (PRWEB) August 30, 2014 Seniors ... several articles recently that focus on Alzheimer’s Disease, Dementia, ... recently revealed to the public of being diagnosed with the ... his latest movie, “I’ll Be Me”. The movie, out ... life while focusing on his diagnosis of the disease – ...
(Date:8/30/2014)... Randy Dotinga HealthDay ... About one in five patients operated on for broken bones ... surgery, a new study finds. Less-educated patients and ... more likely to be "doctor shoppers," said study lead author ... Ky. Overall, he said, the study suggests that doctors aren,t ...
Breaking Medicine News(10 mins):Health News:Natural Vitiligo Treatment Review Exposes Fast Method for Skin Repigmentation 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3
... 6 Prescription pediatric drugs represent,an enormous market, with ... growth is forecast at a modest 3.2%, reaching $43,billion ... share of 11.7%, is,expected to achieve the highest growth ... Kalorama Information,s new report The World Market for,Pediatric Drugs., ...
... Medical Solutions, Inc.,(Rising), a leading medical cost ... Index (PCI) "Top Growth Company" list for ... http://www.newscom.com/cgi-bin/prnh/20080206/AQW030LOGO-b ), (Logo: http://www.newscom.com/cgi-bin/prnh/20080206/AQW030-a ... Inc. ( http://www.entrex.net ), is a,proprietary benchmarking ...
... restatement of Beth Israel Deaconess,Medical Center audit, ... apply the same Sarbanes-Oxley standards used by Massbank ... the board of Beth Israel,Deaconess Medical Center (BIDMC), ... East. Bufferd is also the retired treasurer of,Massachusetts ...
... The Female Health Company,(Amex: FHC ) ... conference call,to discuss its operating results for the ... (EST) on Wednesday, February 13, 2008. The Company ... earlier the same day., Shareholders and other ...
... Medical cost increases for,employers throughout the world ... according to a poll of insurance companies conducted ... The poll also found,that, in a vast majority ... rate of inflation., Nearly three-fourths (71 percent) ...
... A new statewide survey,released today shows that ... tax revenue for programs to prevent kids,from starting ... poll of 500 Virginia voters was released today ... Lung Association and,the Campaign for Tobacco-Free Kids. The ...
Cached Medicine News:Health News:Diabetes, Growth Disorders Drive Sales of Pediatric Hormone Drugs 2Health News:Rising Medical Solutions, Inc. Ranks Fifth on the Private Company Index (PCI) 'Top Growth Companies' List 2Health News:Massbank Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:The Female Health Company Schedules First Quarter Conference Call for February 13, 2008 2Health News:Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds 2Health News:Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds 3Health News:New Poll Shows Virginia Voters Overwhelmingly Favor Funding for Tobacco Prevention 2Health News:New Poll Shows Virginia Voters Overwhelmingly Favor Funding for Tobacco Prevention 3
1000 L, Racked, Pre-sterilized, 100 tips/rack Recommended for 500 and 1000 L pipettes....
300 L, Racked, Filtered, Pre-sterilized, 96 tips/rack Recommended for 250 and 300 L pipettes....
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
... Eliminate aerosol contamination, which ... in PCR. Hydrophobic, nonwicking ... air can pass through ... in contrast to tips ...
Medicine Products: